HALO
Halozyme Therapeutics, Inc (HALO) Sec Form 8K
Halozyme Therapeutics, Inc (NASDAQ: HALO) Sec Form 8K
Halozyme Therapeutics, Inc (HALO) Halozyme Appoints David Ramsay as Interim Chief Financial Officer
Halozyme Therapeutics, Inc (NASDAQ: HALO) FY 2026 Management Update
Halozyme Therapeutics, Inc (HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc (NASDAQ: HALO) Q4 2025 Earnings Call dated Feb. 17, 2026 Corporate Participants: Tram Bui — Head of…
Halozyme Therapeutics, Inc (HALO) U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
Halozyme Therapeutics, Inc (NASDAQ: HALO) FY 2026 Other Release
Halozyme Therapeutics, Inc (HALO) Leerink Partners Global Healthcare Conference
Halozyme Therapeutics, Inc (NASDAQ: HALO) FY 2026 Corporate Conference
Halozyme Therapeutics, Inc (HALO) TD Cowen 46th Annual Healthcare Conference
Halozyme Therapeutics, Inc (NASDAQ: HALO) FY 2026 Corporate Conference
Halozyme Therapeutics, Inc (HALO) Sec Form 10K
Halozyme Therapeutics, Inc (NASDAQ: HALO) Sec Form 10K
Halozyme Therapeutics, Inc (HALO) Sec Form 8K
Halozyme Therapeutics, Inc (NASDAQ: HALO) Sec Form 8K
Halozyme Therapeutics, Inc (HALO) Reiterates Strong 2026 Financial Guidance
Halozyme Therapeutics, Inc (NASDAQ: HALO) FY 2026 Other Release
Halozyme Therapeutics, Inc (HALO) Q4 2025 Earnings Results
Halozyme Therapeutics, Inc (NASDAQ: HALO) Q4 2025 Earnings Release